RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the journal Allergy has published data from the APeX-J trial, a randomized, placebo-controlled trial conducted in Japan evaluating oral, once-daily berotralstat for the prophylactic treatment of hereditary angioedema (HAE).
The APeX-J trial met its primary endpoint of a reduction in the rate of HAE attacks for berotralstat 150 mg compared to placebo during the 24-week period (p=0.003). Berotralstat was safe and generally well-tolerated in the trial.
These results are consistent with the global phase 3 APeX-2 trial, where berotralstat 150 mg also reduced the rate of HAE attacks compared to placebo (p<0.001) and was safe and generally well-tolerated.
APeX-J is the first placebo-controlled trial of an HAE medicine conducted in Japan and the berotralstat data are very exciting for patients, who currently have no approved prophylactic treatment options. Based on the safety and efficacy profile, I believe berotralstat, if approved, would be an important advancement in HAE management for Japanese patients, said Dr. Isao Ohsawa, president of Saiyu Soka hospital and principal investigator of the APeX-J trial.
Dr. Ohsawa and the study authors note that HAE is estimated to affect 2,500 patients in Japan and the recognition of HAE by physicians is low. Although two on-demand treatments are approved, no therapies are currently approved for long-term prophylaxis in Japan.
Berotralstat would be the first approved prophylactic therapy for HAE patients in Japan and we believe there is a significant opportunity for berotralstat to accelerate the diagnosis of HAE patients and dramatically improve the quality of life for patients, said Jon Stonehouse, president and chief executive officer of BioCryst.
A new drug application (JNDA) is under review in Japan for approval of oral, once-daily berotralstat for the prophylactic treatment of HAE. Berotralstat is being reviewed under Sakigake designation and the company expects a decision on approval in December 2020.
Torii Pharmaceutical, Co., Ltd. is BioCrysts commercial partner in Japan for berotralstat.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including ORLADEYO (berotralstat), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at http://www.BioCryst.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements are identified by use of terms such as believe, will, would, expect, and similar words, although some forward-looking statements may be expressed differently. These statements involve known and unknown risks, uncertainties and other factors which may causeactual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCrysts business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCrysts and its partners development, regulatory processes and supply chains, negatively impact BioCrysts ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; developing and commercializing ORLADEYO or any HAE product candidate may take longer or may be more expensive than planned; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA, EMA, PMDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, may impose a clinical hold with respect to such product candidates, or may withhold or delay market approval for product candidates; product candidates, if approved, may not achieve market acceptance; BioCrysts ability to successfully commercialize its product candidates, manage its growth, and compete effectively; and risks related to the international expansion of BioCrysts business. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specificallyBioCrystsmost recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained inBioCrystsforward-looking statements.
BCRXW
Contacts:John Bluth+1 919 859 7910jbluth@biocryst.com
Catherine Collier Kyroulis+1 917 886 5586ckyroulis@biocryst.com
Read the original here:
Allergy Publishes Results from BioCryst's APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks - GlobeNewswire
- Utilizing your free, preventative healthcare coverage - KELOLAND.com - February 18th, 2024
- Preventive Pros: the Podcast - Department of Population and Public Health Sciences - University of Southern California - February 18th, 2024
- Heart health awareness and preventative care with Jen Lewis on Coast Live - News 3 WTKR Norfolk - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - American Heart Association - February 18th, 2024
- Preventive health care benefits | Opinion | thecabin.net - Log Cabin Democrat - February 18th, 2024
- Menopause and migraines: New findings point to power of prevention - Medical Xpress - February 18th, 2024
- How Young Is Too Young For Preventative Skincare? Here's What Experts Want You To Know - Health.com - February 18th, 2024
- Potential prevention of rheumatoid arthritis with injection? Clinical study brings hope for millions - WION - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - Medical Xpress - February 18th, 2024
- Stay on top of your fur baby's health: the importance of scheduling routine vet visits - FoxReno.com - May 17th, 2023
- Preventive healthcare - May 9th, 2023
- What Is Preventive Health and Why Is It Important? - May 9th, 2023
- What Is Preventive Medicine & Why Do We Need It? | AUC - February 16th, 2023
- Preventive Medicine | Journal | ScienceDirect.com by Elsevier - December 3rd, 2022
- Migraine - Diagnosis and treatment - Mayo Clinic - December 3rd, 2022
- Functional Medicine of Idaho | Preventative Root Cause Medicine - December 3rd, 2022
- These 2 Staten Island nurses believe IV hydration drips and vitamin shots are key to long-term health - SILive.com - December 3rd, 2022
- CNBCTV-18 and IIM-K's India@2047 Leadership Series: Challenges and opportunities in the fintech and healthcare sectors - Forbes India - December 3rd, 2022
- As N.W.T. mulls health coverage changes, petition calls for preventative HIV drug to be free - CBC.ca - September 20th, 2022
- EU regulator backs wider use of AstraZeneca COVID therapy - Reuters - September 20th, 2022
- Choose integrative medicine for health and wellness - Technique - September 20th, 2022
- The high hospital bills we make victims of rape and sexual violence pay - Vox.com - September 20th, 2022
- 4 Anti-Aging Products Youre Using All Wrong, According To Skincare Experts - SheFinds - September 20th, 2022
- Why Now is the Time to Double Down on Virtual Care - HIT Consultant - September 20th, 2022
- Tell Giselle: The price of good help is priceless - Wilkes Barre Times-Leader - September 20th, 2022
- Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - BioSpace - September 20th, 2022
- Pickleball injuries are on the rise: 5 preventive tips to keep you on the court - The Manual - September 20th, 2022
- The next big social movement and other takeaways from our regular meeting - POLITICO - September 20th, 2022
- 15 Mushrooms and How to Use Them in Vegan Cooking - VegNews - September 20th, 2022
- Use of honey in the management of Chemotherapy | CMAR - Dove Medical Press - September 20th, 2022
- Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes - September 20th, 2022
- C2C Care Course The Preservation of Our Global Photographic Heritage: Here, There and Everywhere - aam-us.org - August 3rd, 2022
- Loneliness: Causes, Effects And Prevention Forbes Health - Forbes - August 3rd, 2022
- Prevention and wellness is the new model, a leader from Henry Ford Health System says - Becker's Hospital Review - August 3rd, 2022
- FACT SHEET: White House Summit on Building Lasting Eviction Prevention Reform - The White House - August 3rd, 2022
- Getting Back to Employer Health and Wellness Programs - Cone Health - August 3rd, 2022
- Do ICDs Still Work in Primary Prevention Given Today's HF Meds? - Medscape - August 3rd, 2022
- Alzheimer's-defying brain offers clues to treatment, prevention - Harvard Gazette - August 3rd, 2022
- Wind-fanned lightning fire prompted precautionary evacuation notices near Medical Springs Sunday evening - Baker City Herald - August 3rd, 2022
- Experts discuss importance of cancer screenings and early detection - Merck - August 3rd, 2022
- King Institute of Preventive Medicine and Research to test samples for monkeypox - The Hindu - August 3rd, 2022
- Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations - World - ReliefWeb - August 3rd, 2022
- Dr. Sanjay Gupta: While monkeypox cases rise, why are we waiting for the cavalry to rescue us? - CNN - August 3rd, 2022
- SCYNEXIS Announces U.S. Food and Drug Administration - GlobeNewswire - August 3rd, 2022
- Governor Whitmer declares August 2022 as Breastfeeding Month, highlights additional breastfeeding observances - Michigan (.gov) - August 3rd, 2022
- New student education program supports drug and alcohol abuse prevention - The Ohio State University News - July 25th, 2022
- Suicide prevention training for health care providers a first step in longer-term efficacy - University of Washington - July 25th, 2022
- Pharmalittle: Congress may miss deadline to pass FDA user-fee bill; ViiV is urged to lower price for its HIV prevention drug - STAT - July 25th, 2022
- Prevention of Bipolar Disorder Episodes: Is It Possible? - PsychCentral.com - July 25th, 2022
- GAO Found Gap in Dirty Bomb Prevention - Government Technology - July 25th, 2022
- Florida man in apparent medical distress crashes car through beach crowd before hitting the water - CNN - July 25th, 2022
- Study: Preventive care scarce in LGBTQ+ community - - Medical Marketing and Media - July 25th, 2022
- The rise of preventive insurance purchases in India - ETHealthWorld - July 25th, 2022
- Why Are My Feet Always Cold? Cold Feet Causes and Treatment - Prevention Magazine - July 25th, 2022
- Agency looking to open overdose prevention site in Saint John amid 'poisoned' drug supply - CBC.ca - July 25th, 2022
- UVA Expert Offers Insight on the Use of Dietary Supplements for Cancer Prevention - UVA Today - July 25th, 2022
- Alzheimer's: Targeting key protein in blood may slow progression - Medical News Today - July 25th, 2022
- NPPC, FAS focused on ASF prevention in the Philippines - MEAT+POULTRY - July 25th, 2022
- Implementation of IPT in people living with HIV | RMHP - Dove Medical Press - July 25th, 2022
- NL starts preventive vaccination against monkeypox in Amsterdam, The Hague - NL Times - July 25th, 2022
- Precautionary measures you can take against brain haemorrhage - Times of India - July 25th, 2022
- Acid Reflux and Liver Disease: Signs, Symptoms and Prevention - Healthline - July 25th, 2022
- What to do if you get an allergic reaction: symptoms, causes, and prevention - Fox News - July 25th, 2022
- How one woman took control of her rare disease and achieved her dream - Times of Oman - July 25th, 2022
- Tilman Fertitta donating $50 million to UH medical school, which will be renamed after him - Houston Chronicle - May 20th, 2022
- This new 3D screensaver collection includes a driving tour of global pylons - Rock Paper Shotgun - May 20th, 2022
- Dedication, generosity and compassion that had no limit! - The Sun Chronicle - May 20th, 2022
- Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical... - May 20th, 2022
- Tips on avoiding mosquitos this summer - morethanthecurve.com - May 20th, 2022
- Nanomedicine and HIV Therapeutics - AZoNano - May 20th, 2022
- The HIV Vaccine: What We Know, And What We Don't - MadameNoire - May 20th, 2022
- What we know (and don't know) about North Korea's COVID-19 outbreak - WCVB Boston - May 20th, 2022
- Experts warn of health effects from dusty conditions as sandstorm blankets UAE - Al Arabiya English - May 20th, 2022
- Statin therapy: Does the gut microbiome affect outcomes? - Medical News Today - May 20th, 2022
- New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News - November 7th, 2021
- MPD working with faith-based leaders to fight violent crime - FOX13 Memphis - November 7th, 2021
- Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com - November 7th, 2021
- Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner - November 7th, 2021
- Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie - November 7th, 2021
- The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News - November 7th, 2021